Michela E Burlone1, Mattia Bellan1,2, Matteo N Barbaglia2, Ginevra Mocchetti2, Venkata R Mallela2, Rosalba Minisini2, Cristina Rigamonti1,2, Mario Pirisi3,4. 1. Internal Medicine, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy. 2. Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, Novara, Italy. 3. Internal Medicine, Azienda Ospedaliero-Universitaria "Maggiore Della Carità", Novara, Italy. mario.pirisi@uniupo.it. 4. Department of Translational Medicine (DiMeT), Università del Piemonte Orientale, Novara, Italy. mario.pirisi@uniupo.it.
Abstract
BACKGROUND: Genetic predisposition to accumulate liver fat (expressed by a polygenic risk score, GRS, based on the number of at-risk alleles of PNPLA3, TM6SF2, MBOAT7 and GCKR) may influence the probability of developing hepatocellular carcinoma (HCC) after hepatitis C treatment. Whether this holds true taking into account carriage of the HSD17B13:TA splice variant, also affecting lipogenesis, and achievement of viral clearance (SVR), is unknown. METHODS: PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13 variants were determined in a cohort of 328 cirrhotic patients free of HCC before starting treatment with direct acting antivirals (DAA). RESULTS: SVR in the study cohort was 96%. At the end of follow-up, N = 21 patients had been diagnosed an HCC; none of the genes included in the GRS was individually associated with HCC development. However, in a Cox proportional hazards model, a GRS > 0.457 predicted HCC independently of sex, diabetes, albumin, INR and FIB4. The fit of the model improved adding treatment outcome and carriage of the HSD17B13:TA splice variant, with sex, GRS > 0.457, HSD17B13:TA splice variant and failure to achieve an SVR (hazard ratio = 6.75, 4.24, 0.24 and 7.7, respectively) being independent predictors of HCC. CONCLUSION: Our findings confirm that genes modulating liver fat and lipogenesis are important risk factors for HCC development among cirrhotics C treated with DAA.
BACKGROUND: Genetic predisposition to accumulate liver fat (expressed by a polygenic risk score, GRS, based on the number of at-risk alleles of PNPLA3, TM6SF2, MBOAT7 and GCKR) may influence the probability of developing hepatocellular carcinoma (HCC) after hepatitis C treatment. Whether this holds true taking into account carriage of the HSD17B13:TA splice variant, also affecting lipogenesis, and achievement of viral clearance (SVR), is unknown. METHODS: PNPLA3, TM6SF2, MBOAT7, GCKR and HSD17B13 variants were determined in a cohort of 328 cirrhotic patients free of HCC before starting treatment with direct acting antivirals (DAA). RESULTS: SVR in the study cohort was 96%. At the end of follow-up, N = 21 patients had been diagnosed an HCC; none of the genes included in the GRS was individually associated with HCC development. However, in a Cox proportional hazards model, a GRS > 0.457 predicted HCC independently of sex, diabetes, albumin, INR and FIB4. The fit of the model improved adding treatment outcome and carriage of the HSD17B13:TA splice variant, with sex, GRS > 0.457, HSD17B13:TA splice variant and failure to achieve an SVR (hazard ratio = 6.75, 4.24, 0.24 and 7.7, respectively) being independent predictors of HCC. CONCLUSION: Our findings confirm that genes modulating liver fat and lipogenesis are important risk factors for HCC development among cirrhotics C treated with DAA.
Authors: Vincenza Calvaruso; Giuseppe Cabibbo; Irene Cacciola; Salvatore Petta; Salvatore Madonia; Alessandro Bellia; Fabio Tinè; Marco Distefano; Anna Licata; Lydia Giannitrapani; Tullio Prestileo; Giovanni Mazzola; Maria Antonietta Di Rosolini; Licia Larocca; Gaetano Bertino; Antonio Digiacomo; Francesco Benanti; Luigi Guarneri; Alfonso Averna; Carmelo Iacobello; Antonio Magro; Ignazio Scalisi; Fabio Cartabellotta; Francesca Savalli; Marco Barbara; Antonio Davì; Maurizio Russello; Gaetano Scifo; Giovanni Squadrito; Calogero Cammà; Giovanni Raimondo; Antonio Craxì; Vito Di Marco Journal: Gastroenterology Date: 2018-04-12 Impact factor: 22.682
Authors: María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix Journal: J Hepatol Date: 2016-04-13 Impact factor: 25.083
Authors: Adriaan J van der Meer; Jordan J Feld; Harald Hofer; Piero L Almasio; Vincenza Calvaruso; Conrado M Fernández-Rodríguez; Soo Aleman; Nathalie Ganne-Carrié; Roberta D'Ambrosio; Stanislas Pol; Maria Trapero-Marugan; Raoel Maan; Ricardo Moreno-Otero; Vincent Mallet; Rolf Hultcrantz; Ola Weiland; Karoline Rutter; Vito Di Marco; Sonia Alonso; Savino Bruno; Massimo Colombo; Robert J de Knegt; Bart J Veldt; Bettina E Hansen; Harry L A Janssen Journal: J Hepatol Date: 2016-10-22 Impact factor: 25.083
Authors: Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti Journal: J Hepatol Date: 2016-06-24 Impact factor: 25.083
Authors: Oluwaseun Falade-Nwulia; Catalina Suarez-Cuervo; David R Nelson; Michael W Fried; Jodi B Segal; Mark S Sulkowski Journal: Ann Intern Med Date: 2017-03-21 Impact factor: 25.391